Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072

Conditions:   Hyperlipidemias;   Hypertension Interventions:   Drug: AD-2071 10/20mg;   Drug: AD-2072 80/5mg;   Drug: AD-2071 10/20mg + AD2072 80/5mg Sponsor:   Addpharma Inc. Not yet recruiting

Source: ClinicalTrials.gov - August 15, 2018 Category: Research Source Type: clinical trials